These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29043405)

  • 41. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
    Serebruany VL; DiNicolantonio JJ
    Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.
    Deharo P; Cuisset T
    Trends Cardiovasc Med; 2020 May; 30(4):198-202. PubMed ID: 31182263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent developments in antiplatelet therapy after percutaneus coronary intervention.
    Yildiz M; Yildiz BS; Gursoy MO; Akin I
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(3):225-30. PubMed ID: 25174713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
    Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA;
    J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
    Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Costa F; van Klaveren D; James S; Heg D; Räber L; Feres F; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Zanchin T; Palmerini T; Wallentin L; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    Lancet; 2017 Mar; 389(10073):1025-1034. PubMed ID: 28290994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
    Vengoechea F
    Hosp Pract (1995); 2014 Aug; 42(3):33-47. PubMed ID: 25255405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selection of P2Y
    Tantry US; Navarese EP; Myat A; Gurbel PA
    Prog Cardiovasc Dis; 2018; 60(4-5):460-470. PubMed ID: 29339168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease].
    Gulizia MM; Colivicchi F; Abrignani MG; Ambrosetti M; Aspromonte N; Barile G; Caporale R; Casolo G; Chiuini E; Di Lenarda A; Faggiano P; Gabrielli D; Geraci G; La Manna AG; Maggioni AP; Marchese A; Massari FM; Mureddu GF; Musumeci G; Nardi F; Panno AV; Pedretti RFE; Piredda M; Pusineri E; Riccio C; Rossini R; Scotto Di Uccio F; Urbinati S; Varbella F; Zito GB; De Luca L
    G Ital Cardiol (Rome); 2018 May; 19(5):263-331. PubMed ID: 29853716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
    Olivier CB; Diehl P; Bode C; Moser M
    Herz; 2014 Nov; 39(7):808-13. PubMed ID: 25359405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
    Stähli BE; Landmesser U
    Herz; 2018 Feb; 43(1):11-19. PubMed ID: 29236148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.
    Elserwey A; Jabbour RJ; Curzen N
    Future Cardiol; 2024; 20(9):499-515. PubMed ID: 39093436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.